arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Tonix Pharmaceuticals Holding Corp.

TNXP
$4.59 ▼ -0.51 (-10.00%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
69 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
19
Health
Poor
Bearish
auto_awesome

Analytical Summary

Tonix Pharmaceuticals Holding Corp. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $76.4M
Dividend Yield —
Revenue Growth 577.9% ↗
Op. Margin -314.1%
ROIC -15.1% ↘
FCF / Share $-2.57 ↗
Trailing P/E —
Price / Book 0.4x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

69-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$13.54M
↑ +577.9% —
Net Income Profit after all expenses
$-40.19M
↓ -138.8% —
FCF / Share Free cash flow per share
$-2.57
↑ +19.8% —
Long-Term Debt Long-term obligations
$8.65M
↓ -7.5% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓
17
Financial Health ↓
4
Cash Quality ↓
56

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 20 years · 69 quarters